Drug Profile
Contusugene ladenovec - Gendux/Introgen
Alternative Names: Ad-p53; Ad5CMV-p53; Adenoviral p53; ADVEXIN; Contusugene ladenovec Gendux; INGN 201; RPR/INGN 201Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Gendux; Introgen Therapeutics
- Developer Gendux; Introgen Therapeutics; National Cancer Institute (USA)
- Class Antineoplastics; Gene therapies
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Glioblastoma; Head and neck cancer; Li-Fraumeni syndrome; Non-small cell lung cancer; Oesophageal cancer; Orofacial cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 05 Nov 2009 Discontinued - Clinical-Phase-Unknown for Li-Fraumeni syndrome in USA (IV)
- 05 Nov 2009 Discontinued - Phase-I for Bladder cancer in USA (Intratumoural)
- 05 Nov 2009 Discontinued - Phase-I for Bronchiolo alveolar adenocarcinoma in USA (Intratracheal)